Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report)’s share price reached a new 52-week low on Monday. The stock traded as low as $18.68 and last traded at $18.5670, with a volume of 196,905 shares changing hands. The stock had previously closed at $20.00.

Trending Headlines about Structure Therapeutics

Here are a few of the latest headlines about GPCR:

  • Positive Sentiment: HC Wainwright retained its Buy rating, signaling continued confidence despite revising estimates. Structure Therapeutics analyst coverage
  • Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $2.18 per share from $1.84, and reduced its Q4 2026 estimate to a loss of $0.68 from $0.50. The analyst also projects annual losses through FY2030, including $2.40 per share in FY2027. These lower estimates point to higher expected losses and are the clearest negative catalyst in the recent reports. HC Wainwright FY2026 earnings opinion

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Weiss Ratings raised shares of Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. HC Wainwright restated a “buy” rating on shares of Structure Therapeutics in a research note on Thursday. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday, August 7th. Finally, Wall Street Zen downgraded Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $110.91.

Get Our Latest Research Report on GPCR

Structure Therapeutics Trading Down 6.4%

The business has a 50-day moving average price of $27.88 and a 200 day moving average price of $46.06. The stock has a market capitalization of $1.30 billion, a P/E ratio of -14.52 and a beta of -1.12.

Structure Therapeutics (NASDAQ:GPCR – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). On average, sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -2.10 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Orbimed Advisors LLC lifted its stake in Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after acquiring an additional 313,600 shares during the period. Janus Henderson Group PLC increased its position in Structure Therapeutics by 5.2% during the 1st quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after buying an additional 264,833 shares in the last quarter. Siren L.L.C. raised its stake in Structure Therapeutics by 23.2% in the first quarter. Siren L.L.C. now owns 1,328,698 shares of the company’s stock valued at $64,043,000 after buying an additional 250,000 shares during the last quarter. SEB Asset Management AB acquired a new stake in Structure Therapeutics in the first quarter worth about $11,811,000. Finally, Bank of America Corp DE grew its stake in shares of Structure Therapeutics by 617.0% during the first quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock worth $10,948,000 after acquiring an additional 195,454 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

Read More

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.